184 related articles for article (PubMed ID: 17596116)
1. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin.
Hess G; Sanders KN; Hill J; Liu LZ
Am J Manag Care; 2007 Jun; 13 Suppl 3():S80-5. PubMed ID: 17596116
[TBL] [Abstract][Full Text] [Related]
2. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Rublee DA; Burke JP
Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
[TBL] [Abstract][Full Text] [Related]
3. Switching from atorvastatin to simvastatin in patients at high cardiovascular risk: effects on low-density lipoprotein cholesterol.
Aronow HD; Hess G; Hill J; Kuznik A; Liu LZ
Am J Ther; 2010; 17(2):167-75. PubMed ID: 19770794
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
[TBL] [Abstract][Full Text] [Related]
5. Drug utilization patterns and cardiovascular outcomes in elderly patients newly initiated on atorvastatin or simvastatin.
Swindle JP; Potash J; Kulakodlu M; Kuznik A; Buikema A
Am J Geriatr Pharmacother; 2011 Dec; 9(6):471-82. PubMed ID: 22019005
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
7. Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting.
Harley CR; Gandhi SK; Anoka N; Bullano MF; McKenney JM
Am J Manag Care; 2007 Dec; 13 Suppl 10():S276-81. PubMed ID: 18095778
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
9. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting.
Fox KM; Gandhi SK; Ohsfeldt RL; Davidson MH
Am J Manag Care; 2007 Dec; 13 Suppl 10():S270-5. PubMed ID: 18095777
[TBL] [Abstract][Full Text] [Related]
10. Managed care trends in statin usage.
Bazalo GR
Manag Care; 2001 Oct; 10(10):48-50, 53-9. PubMed ID: 11688111
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
12. Impact of patient and plan design factors on switching to preferred statin therapy.
Cox ER; Kulkarni A; Henderson R
Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
14. Impact of out-of-pocket expenses on discontinuation of statin therapy: a cohort study in Finland.
Helin-Salmivaara A; Korhonen MJ; Alanen T; Huupponen R
J Clin Pharm Ther; 2012 Feb; 37(1):58-64. PubMed ID: 21410736
[TBL] [Abstract][Full Text] [Related]
15. A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in hypertensive patients without prior cardiovascular disease.
Foody JM; Joyce AT; Jeffers BW; Liu LZ; Benner JS
Am J Ther; 2011; 18(2):110-6. PubMed ID: 20216383
[TBL] [Abstract][Full Text] [Related]
16. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
18. Dose-related effect of statins on atrial fibrillation after cardiac surgery.
Kourliouros A; De Souza A; Roberts N; Marciniak A; Tsiouris A; Valencia O; Camm J; Jahangiri M
Ann Thorac Surg; 2008 May; 85(5):1515-20. PubMed ID: 18442529
[TBL] [Abstract][Full Text] [Related]
19. Use of high-intensity statin therapy with simvastatin 80 mg and atorvastatin 80 mg in primary care.
Meek CL; Reston JD; Ramsbottom T; Pathmanathan H; Viljoen A
Int J Clin Pract; 2011 Feb; 65(2):120-6. PubMed ID: 21235694
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
